GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000218110 | Cervix | CC | cytoplasmic translation | 96/2311 | 148/18723 | 4.87e-51 | 2.91e-47 | 96 |
GO:000989610 | Cervix | CC | positive regulation of catabolic process | 109/2311 | 492/18723 | 5.26e-10 | 6.99e-08 | 109 |
GO:003133110 | Cervix | CC | positive regulation of cellular catabolic process | 91/2311 | 427/18723 | 9.64e-08 | 5.25e-06 | 91 |
GO:00163587 | Cervix | CC | dendrite development | 58/2311 | 243/18723 | 4.52e-07 | 1.76e-05 | 58 |
GO:00064029 | Cervix | CC | mRNA catabolic process | 56/2311 | 232/18723 | 4.81e-07 | 1.83e-05 | 56 |
GO:19001517 | Cervix | CC | regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay | 11/2311 | 18/18723 | 1.37e-06 | 4.55e-05 | 11 |
GO:19033119 | Cervix | CC | regulation of mRNA metabolic process | 64/2311 | 288/18723 | 1.71e-06 | 5.64e-05 | 64 |
GO:00064019 | Cervix | CC | RNA catabolic process | 62/2311 | 278/18723 | 2.18e-06 | 6.56e-05 | 62 |
GO:003425010 | Cervix | CC | positive regulation of cellular amide metabolic process | 40/2311 | 162/18723 | 1.11e-05 | 2.41e-04 | 40 |
GO:00002896 | Cervix | CC | nuclear-transcribed mRNA poly(A) tail shortening | 13/2311 | 29/18723 | 1.48e-05 | 2.93e-04 | 13 |
GO:00609965 | Cervix | CC | dendritic spine development | 28/2311 | 99/18723 | 1.61e-05 | 3.15e-04 | 28 |
GO:00602119 | Cervix | CC | regulation of nuclear-transcribed mRNA poly(A) tail shortening | 9/2311 | 15/18723 | 1.63e-05 | 3.17e-04 | 9 |
GO:19001536 | Cervix | CC | positive regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay | 9/2311 | 15/18723 | 1.63e-05 | 3.17e-04 | 9 |
GO:000641710 | Cervix | CC | regulation of translation | 89/2311 | 468/18723 | 1.86e-05 | 3.46e-04 | 89 |
GO:00009567 | Cervix | CC | nuclear-transcribed mRNA catabolic process | 30/2311 | 112/18723 | 2.60e-05 | 4.37e-04 | 30 |
GO:00602139 | Cervix | CC | positive regulation of nuclear-transcribed mRNA poly(A) tail shortening | 8/2311 | 13/18723 | 3.85e-05 | 6.05e-04 | 8 |
GO:00002886 | Cervix | CC | nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay | 18/2311 | 56/18723 | 8.42e-05 | 1.13e-03 | 18 |
GO:004572710 | Cervix | CC | positive regulation of translation | 33/2311 | 136/18723 | 9.09e-05 | 1.20e-03 | 33 |
GO:00506849 | Cervix | CC | regulation of mRNA processing | 33/2311 | 137/18723 | 1.06e-04 | 1.35e-03 | 33 |
GO:00610139 | Cervix | CC | regulation of mRNA catabolic process | 38/2311 | 166/18723 | 1.07e-04 | 1.36e-03 | 38 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CPEB3 | SNV | Missense_Mutation | | c.1096N>C | p.Gly366Arg | p.G366R | Q8NE35 | protein_coding | deleterious(0.02) | benign(0.261) | TCGA-AN-A0AR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CPEB3 | SNV | Missense_Mutation | | c.19N>C | p.Met7Leu | p.M7L | Q8NE35 | protein_coding | tolerated_low_confidence(0.24) | benign(0.354) | TCGA-B6-A0IH-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
CPEB3 | insertion | Frame_Shift_Ins | rs763864563 | c.188_189insC | p.Ala64GlyfsTer258 | p.A64Gfs*258 | Q8NE35 | protein_coding | | | TCGA-AR-A5QN-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | taxotere | SD |
CPEB3 | insertion | Frame_Shift_Ins | novel | c.258_259insGCAAGTGTGTGGCAAGGTGCCGGCATAGTCCCAGGATG | p.Pro87AlafsTer46 | p.P87Afs*46 | Q8NE35 | protein_coding | | | TCGA-B6-A0IB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
CPEB3 | SNV | Missense_Mutation | rs764406144 | c.1653C>G | p.Ile551Met | p.I551M | Q8NE35 | protein_coding | deleterious(0) | probably_damaging(0.973) | TCGA-C5-A7CK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
CPEB3 | SNV | Missense_Mutation | | c.1280C>T | p.Pro427Leu | p.P427L | Q8NE35 | protein_coding | deleterious(0) | possibly_damaging(0.621) | TCGA-EA-A50E-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
CPEB3 | SNV | Missense_Mutation | novel | c.645N>G | p.Ile215Met | p.I215M | Q8NE35 | protein_coding | tolerated(0.35) | benign(0.276) | TCGA-VS-A958-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
CPEB3 | SNV | Missense_Mutation | novel | c.1544N>G | p.Val515Gly | p.V515G | Q8NE35 | protein_coding | deleterious(0) | possibly_damaging(0.897) | TCGA-A6-6141-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | 5-fu | SD |
CPEB3 | SNV | Missense_Mutation | | c.1712N>A | p.Arg571His | p.R571H | Q8NE35 | protein_coding | deleterious(0.03) | benign(0.263) | TCGA-A6-6653-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
CPEB3 | SNV | Missense_Mutation | novel | c.1682G>A | p.Arg561Gln | p.R561Q | Q8NE35 | protein_coding | deleterious(0.01) | possibly_damaging(0.831) | TCGA-AA-3672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |